TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00705107

Intervention type: BIOLOGICAL
Intervention: PegIntron pen (peginterferon alfa-2b; SCH 54031)
Description: PegIntron administered in accordance with approved labeling.

Intervention type: DRUG
Intervention: Rebetol (ribavirin; SCH 18908)
Description: Rebetol administered in accordance with approved labeling
Study: NCT03925909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eriocitrin
Description: The responsible nutritionists will do 1) Anthropometric Assessment, in which weight data will be collected (kg); height (m); waist circumference (cm), waist circumference (cm) and hip circumference (cm), muscle mass (kg /%) and percentage of fat by means of bioimpedance equipment; 2) Dietary assessment, which will be performed through a 24-hour Food Recall, a 3-day Food Record and a Food Consumption Frequency Questionnaire; 3) Evaluation of the microbiota, for which stool will be collected from the last 24 hours on the day before the beginning of the experiment and at the end of the study (week 12); 3) Biochemical evaluation, which includes the collection of 30 mL of blood to be performed by trained and qualified technicians.
Study: NCT01521702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Description: four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery and Adjuvant chemotherapy
Description: surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
Study: NCT01903954

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 mcg sc weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Orally b.i.d.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: 1000 mg or 1200 mg orally daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: setrobuvir
Description: Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
Study: NCT04191863

Intervention type: OTHER
Intervention: Clinical, EEG and laboratory assessment at presentation
Description: * The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG.

Intervention type: OTHER
Intervention: Clinical, EEG and laboratory assessment at presentation
Description: * The patients' history, clinical, demographic, and laboratory data were acquired.~* The following tests and imaging studies are routinely done for epilepsy patients receiving valproate treatment and developed nocturnal enuresis, blood urea nitrogen (BUN), serum creatinine (Cr), urinary pH (before and after valproate therapy beginning and at enuresis onset), serum levels and therapeutic doses of valproate.~* Urinary tract ultrasonography (with full and void bladder).~* CT brain and EEG.

Intervention type: DRUG
Intervention: Valproate
Description: valproate monotherapy

Intervention type: DRUG
Intervention: Valproate
Description: valproate monotherapy
Study: NCT03757702

Intervention type: OTHER
Intervention: Evaluation
Description: Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.

Intervention type: OTHER
Intervention: Evaluation
Description: Trunk position sense will be evaluated with a digital inclinometer. Trunk reposition test will be used in evaluation.The postural stability will be evaluated with a special balance device in eyes opened and closed position. Ellipse area (mm2) and perimeter (mm) parameters will be recorded.The angles of thoracal kyphosis and lumbar lordosis will be evaluated with a digital inclinometer.
Study: NCT02731612

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive substance
Study: NCT01918566

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tap water
Study: NCT02645630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Right Cervical Manipulation
Description: We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Cervical Manipulation
Description: We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham Cervical Manipulation
Description: The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
Study: NCT01517386

Intervention type: PROCEDURE
Intervention: thoracic surgery
Description: unilateral thoracic surgery under paravertebral block and general anesthesia
Study: NCT01983774

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT03809819

Intervention type: PROCEDURE
Intervention: laparoscopic Vecchietti vaginoplasty
Description: Patients who underwent laparoscopic Vecchietti vaginoplasty

Intervention type: DIAGNOSTIC_TEST
Intervention: FSFI questionnaire
Description: Completion of FSFI questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: FSFI questionnaire
Description: Completion of FSFI questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6 questionnaire
Description: Completion of UDI-6 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: UDI-6 questionnaire
Description: Completion of UDI-6 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7 questionnaire
Description: Completion of IIQ-7 questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: IIQ-7 questionnaire
Description: Completion of IIQ-7 questionnaire
Study: NCT02467842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NBP607-QIV
Description: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NBP607-Y
Description: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NBP607-V
Description: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria
Study: NCT02820506

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLN mapping and removal of PET-positive lymph nodes
Description: Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLN mapping and removal of PET-positive lymph nodes
Description: Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
Study: NCT06136130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tortoise Positioning Material Group
Description: Preterm infants were placed in the nest with positioning material and placed in lateral and prone positions The positioning material and hand-face maneuver were applied together to the preterm infants in the Positioning Material Group 2, and they were given lateral and prone positions in this way
Study: NCT02423980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon
Study: NCT01791101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Study: NCT03526510

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventionally Fractionated versus Hypofractionated Boost

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventionally Fractionated versus Hypofractionated Boost
Study: NCT02551029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsaicin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00875290

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-time glucose sensor
Description: Children assigned to this intervention will use a real-time sensor continuously
Study: NCT04617015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium Bromide
Description: All subjects receive inhaled ipratropium once with measurement of spirometry before and after. Bronchodilator response of subjects with depression is compare to that of subjects without depression.
Study: NCT04306653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH
Description: patients with acute gout will receive 100 IU ACTH IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone
Description: patients with acute gout will receive 6 mg of betamethasone
Study: NCT05606055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
Description: This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
Study: NCT01918566

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube
Study: NCT03611179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: The chemotherapy regimen will be Paclitaxel (175 mg/m2 of body surface area) administered intravenously over 3 h, followed by carboplatin (area under the curve 5) over 1 h, with standard antiemetic and hypersensitivity medications.~In patients who develop dose-limiting peripheral neuropathy or hypersensitivity, paclitaxel will be replaced with docetaxel (75 mg/m2), which is administered intravenously over 1 h.~Bevacizumab (15 mg/kg bodyweight) administered intravenously initially over 90 min (if tolerated, this time can be reduced to 60 min, and could be further reduced to a minimum of 30 min)
Study: NCT03531099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: treatment with focal HIFU
Description: HIFU treatment will be conducted with the Focal One® device. The treatment area will be defined using MRI data and 3D biopsies. A safety distance of at least 9 mm will be defined around the tumor. An intraoperative contrast echocardiographic control will be performed to evaluate the necrotic area. If necessary, additional HIFU lesions will be performed during the same session. In case of residual tumor demonstrated during control biopsies, additional treatment of this tumor with focal HIFU may be proposed.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PSA dosage
Description: PSA dosage will be regularly performed during patient follow up thanks to blood sampling.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA dosage
Description: PSA dosage will be regularly performed during patient follow up thanks to blood sampling.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI exam will be regularly performed during patient follow up.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI exam will be regularly performed during patient follow up.
Study: NCT05606055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIC/FTC/TAF: Bictegravir/emtricitabina/tenofovir alafenamida fumarato
Description: This is a study to assess the impact of immediate ART (FAST ART or SDT) against conventional treatment (CT) on the time to reach an undetectable HIV-1 viral load.
Study: NCT04228432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dedicated and coordinated monitoring
Description: * Coordinated monitoring performed by a dedicated nurse: consultation before hormonotherapy initiation~* Monitoring at home over a period of 6 months using an e-monitoring tool: assessment of adverse events and completion of GIRERD questionnaire at week 3 and week 6.
Study: NCT04067661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHIP
Description: The couples-based HIV prevention intervention consists of four couples counseling sessions focused on relationship skills to decrease HIV risk behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Enhanced standard of care, which includes information and referrals on HIV risk and prevention.
Study: NCT01306383

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SODIS Bottle
Description: SODIS Bottles used by SODIS group to treat their drinking water

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SODIS Bottle
Description: SODIS Bottles used by SODIS group to treat their drinking water
Study: NCT03610373

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Modular Approach to Therapy for Children (MATCH)
Description: MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children (MATCH)
Description: MATCH is a collection of 31 modules that correspond to the treatment procedures included in standard evidence-based treatments for youth depression, anxiety, and behavioral disorders.
Study: NCT04088110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: Pyrotinib were administered 400 mg orally daily. Oral administration within 30 minutes after breakfast, and continuous administration for 21 days for 1 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab were administered every 3 weeks intravenously (8 mg/kg loading doses followed by 6 mg/kg maintenance doses).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitors
Description: The investigator chose an aromatase inhibitor (either anastrozole, letrozole or exemestane 1 mg/2.5 mg/25 mg), once daily, oral.
Study: NCT03582995

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flap Surgery for root coverage with Alloderm and xenograft
Description: A coronally positioned FLAP technique with AlloDerm® GBR and osseous xenograft will be used for root coverage

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tunnel Surgery for root coverage with Alloderm and xenograft
Description: A coronally positioned TUNNEL technique with AlloDerm® GBR and osseous xenograft will be used for root coverage.
Study: NCT00002921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Study: NCT03531099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will have to complete five questionnaires during their follow up : QLQ-C30 (Quality of Life questionnaire), EPIC-26 (The Expanded Prostate Cancer Index Composite), IPSS (International Prostate Score Symptom), IIEF-5 (The International Index of Erectile Function), STAI-YB (State-Trait Anxiety Inventory)
Study: NCT00002921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study: NCT03757377

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BackBeat Moderato System
Description: Eligible patients randomized after optimization phase to PHC ON for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
Study: NCT03531099

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatic biopsies
Description: Prostatic biopsies will be regularly performed during patient follow up.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatic biopsies
Description: Prostatic biopsies will be regularly performed during patient follow up.
Study: NCT03906006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: Drug: ABP-671, single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: Drug: ABP-671, single oral dose
Study: NCT03757377

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: BackBeat Moderato Sytsem
Description: Eligible patients randomized after optimization phase to PHC OFF for 12 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
Study: NCT06525233

Intervention type: OTHER
Intervention: Physiotherapy and rehabilitation
Description: The aerobic exercise is very crucial part of cardiac rehabilitation. This study compares the effects of interval and continuous training which are the two types of aerobic training on persons' life quality and exercise capacity diagnosed coronary artery disease patients.
Study: NCT02410382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: oral dexamethasone 4 mg bid for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo
Study: NCT01959243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine Tartrate
Description: Ophthalmic solution to be applied as directed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Ophthalmic solution to be applied as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Fluorescein
Description: For use as needed during the study for evaluating corneal damage.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Description: For use as needed during the study for intraocular pressure and dilated ophthalmoscopy.
Study: NCT01158391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NTrainer® Intervention

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control Intervention
Study: NCT04514211

Intervention type: DRUG
Intervention: Propofol
Description: General anesthesia using propofol infusion

Intervention type: DRUG
Intervention: Sevoflurane
Description: General anesthesia using sevoflurane
Study: NCT03196531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Xisimin [Test Treatment])
Description: Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine (Clarityne [Reference Treatment])
Description: Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
Study: NCT03080363

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 10 ml %0.5 bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 10 ml %2 lidocaine
Study: NCT03906006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Other: Placebo, single oral dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Other: Placebo, single oral dose
Study: NCT02166827

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroAD
Description: Synchronized TMS and cognitive stimulation to 6 brain areas.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS+Cog
Description: Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
Study: NCT03204981

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intramural Needle Ablation
Description: The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: standard ablation